BACKGROUND: An imbalance in the excitatory/inhibitory systems with abnormalities in the glutamatergic pathways has been implicated in the pathophysiology of autism. Furthermore, chronic redox imbalance was also recently linked to this disorder. The goal of this pilot study was to assess the feasibility of using oral N-acetylcysteine (NAC), a glutamatergic modulator and an antioxidant, in the treatment of behavioral disturbance in children with autism. METHODS: This was a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autistic disorder. Subjects randomized to NAC were initiated at 900 mg daily for 4 weeks, then 900 mg twice daily for 4 weeks and 900 mg three times daily for 4 weeks. The primary behavioral measure (Aberrant Behavior Checklist [ABC] irritability subscale) and safety measures were performed at baseline and 4, 8, and 12 weeks. Secondary measures included the ABC stereotypy subscale, Repetitive Behavior Scale-Revised, and Social Responsiveness Scale. RESULTS:Thirty-three subjects (31 male subjects, 2 female subjects; aged 3.2-10.7 years) were randomized in the study. Follow-up data was available on 14 subjects in the NAC group and 15 in theplacebo group. Oral NAC was well tolerated with limited side effects. Compared with placebo, NAC resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96). CONCLUSIONS: Data from this pilot investigation support the potential usefulness of NAC for treating irritability in children with autistic disorder. Large randomized controlled investigations are warranted.
RCT Entities:
BACKGROUND: An imbalance in the excitatory/inhibitory systems with abnormalities in the glutamatergic pathways has been implicated in the pathophysiology of autism. Furthermore, chronic redox imbalance was also recently linked to this disorder. The goal of this pilot study was to assess the feasibility of using oral N-acetylcysteine (NAC), a glutamatergic modulator and an antioxidant, in the treatment of behavioral disturbance in children with autism. METHODS: This was a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autistic disorder. Subjects randomized to NAC were initiated at 900 mg daily for 4 weeks, then 900 mg twice daily for 4 weeks and 900 mg three times daily for 4 weeks. The primary behavioral measure (Aberrant Behavior Checklist [ABC] irritability subscale) and safety measures were performed at baseline and 4, 8, and 12 weeks. Secondary measures included the ABC stereotypy subscale, Repetitive Behavior Scale-Revised, and Social Responsiveness Scale. RESULTS: Thirty-three subjects (31 male subjects, 2 female subjects; aged 3.2-10.7 years) were randomized in the study. Follow-up data was available on 14 subjects in the NAC group and 15 in the placebo group. Oral NAC was well tolerated with limited side effects. Compared with placebo, NAC resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96). CONCLUSIONS: Data from this pilot investigation support the potential usefulness of NAC for treating irritability in children with autistic disorder. Large randomized controlled investigations are warranted.
Authors: Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric Journal: Psychopharmacology (Berl) Date: 2005-12-22 Impact factor: 4.530
Authors: Rabindra Tirouvanziam; Tetyana V Obukhanych; Julie Laval; Pavel A Aronov; Robin Libove; Arpita Goswami Banerjee; Karen J Parker; Ruth O'Hara; Leonard A Herzenberg; Leonore A Herzenberg; Antonio Y Hardan Journal: J Autism Dev Disord Date: 2012-05
Authors: David J Posey; Deborah L Kem; Naomi B Swiezy; Thayne L Sweeten; Ryan E Wiegand; Christopher J McDougle Journal: Am J Psychiatry Date: 2004-11 Impact factor: 18.112
Authors: Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg Journal: Proc Natl Acad Sci U S A Date: 2006-03-13 Impact factor: 11.205
Authors: Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-11 Impact factor: 8.829
Authors: Elizabeth Nance; Michael Porambo; Fan Zhang; Manoj K Mishra; Markus Buelow; Rachel Getzenberg; Michael Johnston; Rangaramanujam M Kannan; Ali Fatemi; Sujatha Kannan Journal: J Control Release Date: 2015-07-13 Impact factor: 9.776
Authors: Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos Journal: Antioxid Redox Signal Date: 2019-02-01 Impact factor: 8.401
Authors: Michael H Bloch; Kaitlyn E Panza; Jon E Grant; Christopher Pittenger; James F Leckman Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-03 Impact factor: 8.829
Authors: Lawrence Scahill; Sangchoon Jeon; Susan J Boorin; Christopher J McDougle; Michael G Aman; James Dziura; James T McCracken; Sonia Caprio; L Eugene Arnold; Ginger Nicol; Yanhong Deng; Saankari A Challa; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-03-07 Impact factor: 8.829